Nothing Special   »   [go: up one dir, main page]

JPS6442441A - Macrophage activator - Google Patents

Macrophage activator

Info

Publication number
JPS6442441A
JPS6442441A JP62199144A JP19914487A JPS6442441A JP S6442441 A JPS6442441 A JP S6442441A JP 62199144 A JP62199144 A JP 62199144A JP 19914487 A JP19914487 A JP 19914487A JP S6442441 A JPS6442441 A JP S6442441A
Authority
JP
Japan
Prior art keywords
macrophages
formula
expressed
macrophage
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62199144A
Other languages
Japanese (ja)
Inventor
Toshiaki Osawa
Masahiro Higuchi
Tooru Mitsuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denki Kagaku Kogyo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denki Kagaku Kogyo KK filed Critical Denki Kagaku Kogyo KK
Priority to JP62199144A priority Critical patent/JPS6442441A/en
Publication of JPS6442441A publication Critical patent/JPS6442441A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PURPOSE:To obtain a macrophage activator, containing, human lymphotoxin as an active ingredient and capable of imparting chemotaxis to macrophages and accelerating antitumor action. CONSTITUTION:A macrophage activator containing human lymphotoxin (h-LT), preferably rh-LT-1 expressed by formula I (R is formula II) which is h-LT (hereinafter referred to as rh-LT) prepared by using a genetic manipulation technique in aspects of ensuring homogeneous h-LT in an amount so as to enable cancer clinical application, rh-LT-2 expressed by formula III or rh-LT-3 expressed by formula IV as an active ingredient. Methods for activating macrophages collected from an animal abdominal cavity, blood, lung, etc., with the h-LT in.vivo and administering the activated macrophages to a cancerated animal, directly administering the h-LT thereto, accumulating the macrophages in tumorous parts, etc., are used as a method for activating the macrophage and treating cancer.
JP62199144A 1987-08-11 1987-08-11 Macrophage activator Pending JPS6442441A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62199144A JPS6442441A (en) 1987-08-11 1987-08-11 Macrophage activator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62199144A JPS6442441A (en) 1987-08-11 1987-08-11 Macrophage activator

Publications (1)

Publication Number Publication Date
JPS6442441A true JPS6442441A (en) 1989-02-14

Family

ID=16402880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62199144A Pending JPS6442441A (en) 1987-08-11 1987-08-11 Macrophage activator

Country Status (1)

Country Link
JP (1) JPS6442441A (en)

Similar Documents

Publication Publication Date Title
ATE358505T1 (en) COATED ENDOVASCULAR DEVICE
DE602005026078D1 (en) Use of antioxidants to prevent oxidation and to reduce the decomposition of active ingredients in active ingredient-containing medical articles
RU93032613A (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION
BIÖRCK et al. Reactions of Hedgehogs, Hibernating and Non‐hibernating, 40 the Inkahtion of Oxygen, Carbon Dioxide and Nitrogen
DE194851T1 (en) THERAPY OF HUMAN TUMORS.
DE3162614D1 (en) Dibenzoxazepine derivative, process for preparing the same and pharmaceutical composition comprising the same
US5508030A (en) Creating new capillary blood pools for practicing bidirectional medicine
AU3024389A (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
MD545G2 (en) Remedy
Tabaie et al. Reduction of exercise dilation by theophylline
EP0388799A3 (en) Use of human interferon-beta for stimulation of erythropoieses
Gorshein et al. Rapid stem cell differentiation induced by 19‐nortestosterone decanoate
JPS6442441A (en) Macrophage activator
KR100301340B1 (en) Compositions for biological stimulation and correction of biological phenotype and methods for their treatment
Lichti et al. Wound fluid and plasma zinc levels in rats during tissue repair: Sequential determination using surgically implanted stainless steel wound cylinders
EP1763343B1 (en) Calcium trifluoroacetate for preparing antiangiogenetic medicaments
Horn Regular impulse activity of single units in the cat striate cortex
EP0397211A3 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
RU2228763C1 (en) Method for treating the cases of purulent wounds
EP0331088A3 (en) Remedy for hematopoietic tissue diseases comprising human monocytic macrophage colony stimulating factor as active ingredient
NZ222867A (en) Use of epidermal growth factor to enhance iron uptake into the bloodstream and pharmaceutical compositions
SU1685458A1 (en) Method for hepatic coma treatment in viral hepatitis b
SG60292G (en) Medical preparation comprising aspoxicillin,a method for its preparation,and the use of such a preparation for the manufacture of a medicament
Bicker et al. Effects of Immobilon and Revivon on the cardiovascular system and acid base status of the Göttingen minipig
SU1172109A1 (en) Method of treating wounded surfaces in oncologic operations on upper jawbone